Gilead trial for Covid-19 meets primary endpoint

Push stocks higher

  • Gilead Remdesivir trial for Covid-19 has met primary endpoint
  • Study to provide info on 5-day duration of therapy
  • will share added Remdesivir data from phase 3 shortly
  • Seees data from 2nd simple study at the end of May